REGISTER RECORD · ctis
2024-516905-22-00
Induction therapy with bortezomib, melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide and dexamethasone (KRd) with/without daratumumab, 18 cycles, followed by consolidation and maintenance with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for older adult patients between 65 and 80 years old, in good general health with newly-diagnosed multiple myeloma
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | The register records no status for this entry. |
|---|---|
| Register last updated | 2026-09-10 |
| Retrieved by this site | 2026-10-03 |
| Source | https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-516905-22-00 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.